| Beam Therapeutics is a biotechnology company. Within its ex vivo platform, Co. has identified three development candidates. BEAM-101 reproduces single base changes seen in individuals with Hereditary Persistence of Fetal Hemoglobin to potentially protect them from the effects of mutations causing sickle cell disease or beta thalassemia. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. We show 8 historical shares outstanding datapoints in our coverage of BEAM's shares outstanding history.|
Understanding the changing numbers of BEAM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BEAM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BEAM by allowing them to research BEAM shares outstanding history
as well as any other stock in our coverage universe.